Bluefield Innovations, a collaboration between Deerfield Management and the Johns Hopkins University to catalyze early stage therapeutic development, disclosed the acceptance and funding of its first project. The target, the enzyme RNA polymerase I, or Pol I, is implicated in many forms of cancer.